Virginia Commonwealth University

VCU Massey Cancer Center

Massey researcher selected as national leader for large-scale NCI clinical trial

Known as the NCI-MATCH trial – National Cancer Institute Molecular Analysis for Therapy Choice Program, the study will consist of numerous small, phase 2 trials that will examine solid tumors and lymphomas that no longer respond to standard treatment and have begun to grow. Next-generation DNA sequencing will be administered on tumor biopsies from as many as 3,000 patients nationwide to determine the cell’s “broken” mechanism and, therefore, what is causing the cancer growth.

Continue reading →

Common antibiotic part of a promising potential pancreatic cancer therapy

Paul Fisher and Bridget Quinn

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments. 

Continue reading →

Massey researcher leads team to improve data reporting of meningioma treatment outcomes nationwide

A new study led by VCU Massey Cancer Center physician-researcher Leland Rogers, M.D., found that clinical trials to treat the most common primary brain tumor, meningioma, lack uniform guidelines for how physicians should determine whether treatment is effective at shrinking the tumor. The study was published in the Journal of Neurosurgery.

Continue reading →

Massey researcher leads task force to develop first guidelines for evaluating and treating children with thyroid cancer

VCU Massey Cancer Center researcher and Children’s Hospital of Richmond at VCU endocrinologist Gary Francis, M.D., Ph.D., recently led a task force commissioned by the American Thyroid Association (ATA) to develop a set of guidelines for evaluating and treating children with thyroid nodules and cancer. The newly issued guidelines are the first and only set of recommendations aimed at managing patients 18 years of age and younger with thyroid tumors and will provide the best practice standards for diagnosing and treating pediatric thyroid cancer.

Continue reading →

Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

Paul Fisher at his desk.

Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer’s growth.

Continue reading →